

# Special Issue

## Photodynamic Cancer Therapy

### Message from the Guest Editor

Photodynamic therapy (PDT) for cancer came to prominence in 1978, in a landmark publication by Tom Dougherty regarding the use of Photofrin. Since then, hundreds of papers have presented the structures of different novel photosensitizers that could be used for anti-cancer PDT. Many investigators have dissected the signaling pathways and gene expression patterns that lead to cell death or cell survival after PDT.

Nanotechnology is playing an increasingly major role in modern PDT research. Animal models allow testing of new PDT protocols, and, in the case of immunocompetent animals, also allow investigation of the anti-tumor immune response that often occurs after PDT. Clinical trials of PDT for cancer continue to be conducted and new regulatory approvals are eagerly awaited.

---

### Guest Editor

Dr. Michael R. Hamblin

Wellman Center for Photomedicine, Massachusetts General Hospital,  
Boston, MA 02114, USA

---

### Deadline for manuscript submissions

closed (31 July 2016)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/si/6248](https://mdpi.com/si/6248)

*Cancers*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)